Orford Keith 4
4 · Calithera Biosciences, Inc. · Filed Jan 22, 2021
Insider Transaction Report
Form 4
Orford Keith
SR. VP, CLINICAL DEVELOPMENT
Transactions
- Award
Common Stock
2021-01-20+30,000→ 76,094 total - Award
Common Stock
2021-01-20+35,000→ 46,094 total - Award
Employee Stock Option (Right to Buy)
2021-01-20+150,000→ 150,000 totalExercise: $2.98Exp: 2031-01-20→ Common Stock (150,000 underlying)
Footnotes (3)
- [F1]The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall vest as follows: one-fourth (1/4th) of the shares subject to the Restricted Stock Unit will vest each year after January 20, 2021 until the Restricted Stock Units are fully vested. The Restricted Stock Unit shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.
- [F2]The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on January 3, 2022. The Restricted Stock Unit shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.
- [F3]One-fourth (1/4th) of the Option vests one year after January 20, 2021; the balance of the Option vests in a series of thirty-six (36) successive equal monthly installments thereafter. The Option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.